Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Total Liabilities: 2019-2025

Historic Total Liabilities for Lyell Immunopharma (LYEL) over the last 6 years, with Sep 2025 value amounting to $78.8 million.

  • Lyell Immunopharma's Total Liabilities fell 10.93% to $78.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $78.8 million, marking a year-over-year decrease of 10.93%. This contributed to the annual value of $108.0 million for FY2024, which is 13.63% up from last year.
  • According to the latest figures from Q3 2025, Lyell Immunopharma's Total Liabilities is $78.8 million, which was down 8.88% from $86.5 million recorded in Q2 2025.
  • Over the past 5 years, Lyell Immunopharma's Total Liabilities peaked at $334.0 million during Q1 2021, and registered a low of $78.8 million during Q3 2025.
  • Moreover, its 3-year median value for Total Liabilities was $93.3 million (2025), whereas its average is $92.9 million.
  • As far as peak fluctuations go, Lyell Immunopharma's Total Liabilities plummeted by 49.37% in 2023, and later climbed by 13.63% in 2024.
  • Lyell Immunopharma's Total Liabilities (Quarterly) stood at $197.6 million in 2021, then tumbled by 47.22% to $104.3 million in 2022, then decreased by 8.85% to $95.1 million in 2023, then rose by 13.63% to $108.0 million in 2024, then decreased by 10.93% to $78.8 million in 2025.
  • Its Total Liabilities was $78.8 million in Q3 2025, compared to $86.5 million in Q2 2025 and $93.3 million in Q1 2025.